%0 Journal Article
%T [177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide (177Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
%A Andreas W. Kluge
%A Cees J.A. van Echteld
%A Harshad Kulkarni
%A Karin Niepsch
%A Norman Bitterlich
%A Richard P. Baum
%A Ulrike Schorr-Neufing
%J Archive of "Theranostics".
%D 2016
%R 10.7150/thno.13702
%K Neuroendocrine tumour
%K somatostatin receptor
%K peptide receptor
%K radiotherapy
%K radionuclide therapy
%K somatostatin analogue.
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775860/